Literature DB >> 18174868

Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.

Ritei Uehara1, Ermias D Belay, Ryan A Maddox, Robert C Holman, Yosikazu Nakamura, Mayumi Yashiro, Izumi Oki, Hirotaro Ogino, Lawrence B Schonberger, Hiroshi Yanagawa.   

Abstract

BACKGROUND: Some Kawasaki disease (KD) patients do not respond to initial treatment with intravenous immunoglobulin (IVIG). The purpose of this study was to determine potential risk factors associated with IVIG nonresponse among KD patients in Japan.
METHODS: Data were obtained from questionnaires used for the 18th nationwide KD survey of patients who visited hospitals in Japan from 2003 through 2004. Data for patients who met the case definition for KD and received 2 g/kg single infusion IVIG as the initial treatment within 10 days of illness were analyzed. IVIG nonresponders were defined as patients who needed secondary treatment after initial IVIG administration.
RESULTS: Among 15,940 KD patients in Japan during 2003-2004, 6330 patients received 2 g/kg single infusion IVIG within 10 days of illness onset. IVIG nonresponders accounted for 20.3% of them (n = 1286). Male sex [odds ratio (OR), 1.21, 95% confidence interval (CI), 1.06-1.37], receipt of the initial IVIG before the fifth day of illness (OR: 1.89, 95% CI: 1.66-2.15), and having recurrent KD (OR: 1.38, 95% CI: 1.00-1.90) were significantly associated with IVIG nonresponse. In addition, IVIG nonresponders had significantly higher risks for coronary artery aneurysms (OR: 10.38, 95% CI: 6.98-15.45) or giant coronary artery aneurysms (OR: 54.06, 95% CI: 12.84-227.65).
CONCLUSIONS: Physicians should consider potential IVIG nonresponse among recurrent KD patients or KD patients diagnosed and treated before the fifth day of illness, particularly if they are boys and have laboratory values associated with nonresponse such as low platelet count, and elevated alanine aminotransferase and C-reactive protein. Some of these patients may benefit from administration of the alternative secondary treatment early during the illness along with the initial IVIG treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18174868     DOI: 10.1097/INF.0b013e31815922b5

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  52 in total

Review 1.  Use of corticosteroids during acute phase of Kawasaki disease.

Authors:  Jeong Jin Yu
Journal:  World J Clin Pediatr       Date:  2015-11-08

2.  Infliximab treatment for pediatric refractory Kawasaki disease.

Authors:  Laura L Blaisdell; Jennifer A Hayman; Adrian M Moran
Journal:  Pediatr Cardiol       Date:  2011-07-20       Impact factor: 1.655

Review 3.  Treatment Options for Resistant Kawasaki Disease.

Authors:  Linny Kimly Phuong; Nigel Curtis; Peter Gowdie; Jonathan Akikusa; David Burgner
Journal:  Paediatr Drugs       Date:  2018-02       Impact factor: 3.022

4.  Etanercept With IVIg for Acute Kawasaki Disease: A Randomized Controlled Trial.

Authors:  Michael A Portman; Nagib S Dahdah; April Slee; Aaron K Olson; Nadine F Choueiter; Brian D Soriano; Sujatha Buddhe; Carolyn A Altman
Journal:  Pediatrics       Date:  2019-05-02       Impact factor: 7.124

5.  N-terminal pro-brain natriuretic peptide (NT proBNP) as a predictive indicator of initial intravenous immunoglobulin treatment failure in children with Kawasaki disease: a retrospective study.

Authors:  So Youn Kim; Mi Young Han; Sung-Ho Cha; Yang Bin Jeon
Journal:  Pediatr Cardiol       Date:  2013-06-07       Impact factor: 1.655

6.  Effect and Safety of TNF Inhibitors in Immunoglobulin-Resistant Kawasaki Disease: a Meta-analysis.

Authors:  Li-Jun Xue; Rong Wu; Gui-Lian Du; Yan Xu; Kang-Yan Yuan; Zhi-Chun Feng; Yu-Lin Pan; Guang-Yu Hu
Journal:  Clin Rev Allergy Immunol       Date:  2017-06       Impact factor: 8.667

7.  Recurrent Kawasaki disease: USA and Japan.

Authors:  Ryan A Maddox; Robert C Holman; Ritei Uehara; Laura S Callinan; Jodie L Guest; Lawrence B Schonberger; Yosikazu Nakamura; Mayumi Yashiro; Ermias D Belay
Journal:  Pediatr Int       Date:  2015-11-05       Impact factor: 1.524

8.  Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance.

Authors:  Wen Fury; Adriana H Tremoulet; Virginia E Watson; Brookie M Best; Chisato Shimizu; Jennifer Hamilton; John T Kanegaye; Yi Wei; Chiayi Kao; Scott Mellis; Calvin Lin; Jane C Burns
Journal:  Hum Immunol       Date:  2010-06-20       Impact factor: 2.850

9.  The Clinical Profile of Kawasaki Disease in Algerian Children: A Single Institution Experience.

Authors:  Houda Boudiaf; Moussa Achir
Journal:  J Trop Pediatr       Date:  2015-12-09       Impact factor: 1.165

10.  Predicting factors for refractory kawasaki disease.

Authors:  Young-Sun Do; Ki-Won Kim; Jin-Kyong Chun; Byung Ho Cha; Mee Kyung Namgoong; Hae Yong Lee
Journal:  Korean Circ J       Date:  2010-05-27       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.